



SDI Review Form 1.6

Journal Name:	Cardiology and Angiology: An International Journal
Manuscript Number:	Ms_CA_36200
Title of the Manuscript:	Acetyl Salicylic acid and Omega 3 Fatty Acids in the pro resolving pathway of Cardiovascular Disorders
Type of the Article	Review Paper

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	The provided Review needs and extensive English language correction as well as a complete conceptual revision. Author(s) stated cardiovascular diseases (CVDs) on the title and specify high blood pressure (hypertension, HT) in the abstract and conclusions. However, there is no even a separate paragraph mentioned in the text. The whole review represents blocks of different information without any logical connections between or in the end. Instead of describing historical part of aspirin (ASA) production, it might be better to elaborate more on the stated mechanisms of action of both ASA and omega-3 PUFAs and its relation to clinical practice. There are many references lacking in the text and having 31 cited articles is not enough for the review paper. The terms and abbreviations should be unified, there are numerous misspellings and inappropriate terms descriptions. It is not clear what authors stated by term "atherosis"? Also, the sentence 151-152 does not make any sense and should be rewritten as well as some other parts throughout the text.	Respected Sir 1. The conceptual framework is revised in Scheme 1. Figure 1 is added to show the biological actions of omega 3 fatty acids. 2. The title is revised as "Acetyl Salicylic acid and Omega 3 Fatty Acids in the pro resolving pathway of Hypertension" 3. Separate paragraph is added on the omega 3 fatty acids in introduction 4. Current recommendation has been elaborated. A scheme showing the biological effects of aspirin and omega 3 fatty acids has been added as Scheme 1. 5. References are included and the number of references is now 54 6. Atherosclerosis (pleural Atherosclerosis) is sub endothelial deposition of lipid-filled foam cells, fibrinoid necrosis of the arterial wall, perivascular lymphocytic infiltration, and it is similar to early arteriosclerosis. This is added in text lines 66-69 7. Sentence 151-152 is revised as "The Rv and PD molecules do not inhibit the onset of inflammation but stimulate the resolution pathways." Lines 164,165
Minor REVISION comments	Please, correct as omega-3, pro-resolving, cardiovascular diseases. Misspellings in terms, lines 55-56. Please, use appropriate citation software, as EndNote, or re-check the references, there are numerous orthographical and style issues. Fig.2 should be considered for elimination. It might be better to have a pathway scheme instead with pathway markers and enzymes needed for conversion. Figure 3 should have a graphical modification, it is hard to see white text on some of the bright coloured boxes. Table 1 represents information from the guidelines and it is not clear why it needs to be included into this review.	1. Endnote is used to add citations. 2. Figure 2 is eliminated. 3. Figure 3 is typed in black font to improve clarity. 4. Table 1 is removed
Optional/General comments		